On Friday, Shares of Microsoft Corporation (NASDAQ:MSFT), lost -0.38% to $46.70.
Microsoft Corporation has agreed to invest about $100 million in Uber Technologies Inc. at a valuation of about $50 billion, a person with knowledge of the matter said.
The deal was finalized earlier on Friday, said the person, who asked not to be identified discussing a private deal, according to Bloomberg.
Uber, valued at $40 billion when it raised funds earlier this year, is benefiting from investors who view its car-booking technology as the future of transport. The San Francisco-based company, led by Chief Executive Officer Travis Kalanick, is using the cash to expand operations to cities across the globe.
Microsoft Corporation develops, licenses, markets, and supports software, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system.
Shares of The Procter & Gamble Company (NYSE:PG), declined -0.89% to $76.70, during its last trading session, hitting its lowest level, after The Procter & Gamble Company released its latest quarterly earnings results on July 30.
Organic sales, a closely followed metric that strips out currency moves and acquisitions and divestments, were flat in the latest quarter and raised just 1% in the past year, contrast with 3% growth a year earlier, according to WSJ.
Overall, P&G stated quarterly net income of $521 million, or 18 cents a share, down from $2.58 billion, or 89 cents a share, a year earlier. Its net profit for the full year was $7 billion, down 40%. For the fiscal year that ends in June 2016, P&G has forecast flat to slightly higher organic-sales growth. WSJ Reports
The Procter & Gamble Company, together with its auxiliaries, manufactures and sells branded consumer packaged goods. The company operates through five segments: Beauty; Grooming; Health Care; Fabric Care and Home Care; and Baby, Feminine and Family Care.
Finally, Merck & Co. Inc. (NYSE:MRK), ended its last trade with 0.75% gain, and closed at $58.96.
Merck (known as MSD outside the US and Canada) said that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is ongoing, were published on-line recently in The Lancet. The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 - 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination.
To date, more than 4,000 participants have received the vaccine in this innovative trial, called “Ebola ça suffit,” or “Ebola, that’s enough.” The trial was conducted by a team that comprised of researchers from the World Health Organization (WHO), the Norwegian Institute of Public Health, the Health Ministry of Guinea and Médecins sans Frontières, among others. The results from this ongoing study, in addition to other studies already underway and additional studies to be conducted will be used to support worldwide regulatory submissions.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
